"Advance Neuren’s strategy to commercialise trofinetide outside North America, including Europe and Japan
* Engage with regulators to confirm requirements for registration in Rett syndrome
* Progress partnering discussions"
Would seem that a takeover is not on the cards.
Ann: Presentation at AusBiotech Invest and Partnering 2018, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.48 |
Change
0.000(0.00%) |
Mkt cap ! $2.076B | |||
| Open | High | Low | Value | Volume |
| $16.48 | $16.77 | $16.28 | $3.108M | 188.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 105 | $16.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.54 | 885 | 2 |
View Market Depth
| Last trade - 16.13pm 28/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |